Glycan Profiling of Endometrial Cancers Using Lectin Microarray
Overview
Molecular Biology
Authors
Affiliations
Cell surface glycans change during the process of malignant transformation. To characterize and distinguish endometrial cancer and endometrium, we performed glycan profiling using an emerging modern technology, lectin microarray analysis. The three cell lines, two from endometrial cancers [well-differentiated type (G1) and poorly differentiated type (G3)] and one from normal endometrium, were successfully categorized into three independent groups by 45 lectins. Furthermore, in cancer cells, a clear difference between G1 and G3 type was observed for the glycans recognized with six lectins, Ulex europaeus agglutinin I (UEA-I), Sambucus sieboldiana agglutinin (SSA), Sambucus nigra agglutinin (SNA), Trichosanthes japonica agglutinin I (TJA-I), Amaranthus caudatus agglutinin (ACA), and Bauhinia purpurea lectin (BPL). The lectin microarray analysis using G3 type tissues demonstrated that stage I and stage III or IV were distinguished depending on signal pattern of three lectins, Dolichos biflorus agglutinin (DBA), BPL, and ACA. In addition, the analysis of the glycans on the ovarian cancer cells showed that only anticancer drug-sensitive cell lines had almost no activities to specific three lectins. Glycan profiling by the lectin microarray may be used to assess the characteristics of tumors and potentially to predict the success of chemotherapy treatment.
Resnik N, Visnjar T, Smrkolj T, Kreft M, Romih R, Zupancic D Histochem Cell Biol. 2023; 160(5):435-452.
PMID: 37535087 PMC: 10624759. DOI: 10.1007/s00418-023-02224-2.
Zhang Z, Cao Z, Wang J, Li Z, Wang T, Xiang Y Front Endocrinol (Lausanne). 2023; 14:1157487.
PMID: 37435486 PMC: 10331720. DOI: 10.3389/fendo.2023.1157487.
Recognition factors of Dolichos biflorus agglutinin (DBA) and their accommodation sites.
Wu A, Dudek A, Chen Y Glycoconj J. 2023; 40(4):383-399.
PMID: 37266898 DOI: 10.1007/s10719-023-10118-7.
Hires M, Jane E, Kalavska K, Chovanec M, Mego M, Kasak P Cancer Med. 2022; 11(4):968-982.
PMID: 35044085 PMC: 8855906. DOI: 10.1002/cam4.4515.
Sialic acids in gynecological cancer development and progression: Impact on diagnosis and treatment.
Berghuis A, Pijnenborg J, Boltje T, Pijnenborg J Int J Cancer. 2021; 150(4):678-687.
PMID: 34741527 PMC: 9299683. DOI: 10.1002/ijc.33866.